RG
Regencell Bioscience
RGC · NASDAQ
$6.20 +0.16% (+$0.01)
1M +11.98%
Market Cap $3.07B
P/E Ratio -
Div. Yield -
ROE 68.23%
Bulios Fair Price
$3.3
46.8% downside
Current Price
$6.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RGC is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 632.05x
P/FCF N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 34.21%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 62.27%
ROIC 69.75%
Debt
100 /100
Low Current ratio 7.39x
Debt/Equity 0.11x
Net debt/EBITDA N/A
Stability
58 /100
Moderate EPS volatility 4.89%
Profitable years 0
Beta 1.43x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RGC
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Yat-Gai Au
Employees
10
Headquarters
Hong Kong
Upcoming events
28 OCT
Earnings
Upcoming earnings report